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to empiric guidelines of
fibrinogen replacement.
•Monitoring of fibrinogen
levels in patients with
moderate and severe
CRS is essential for
avoiding potentially fatal
bleeding events.
Cytokine release syndrome (CRS) is a systemic inflammatory response associated with
chimeric antigen receptor T-cell (CAR-T) therapies. In severe cases, CRS can be associated
with coagulopathy and hypofibrinogenemia. We present our global multicenter experience
with CRS-associated coagulopathy after tisagenlecleucel therapy in 137 patients with
relapsed or refractory B-cell acute lymphoblastic leukemia from the ELIANA and ENSIGN
trials. These trials included clinical guidelines for fibrinogen replacement during CRS-
associated coagulopathy. Hypofibrinogenemia requiring replacement was observed only in
patients with severe CRS. A higher percentage of patients who required replacement were
,10 years old, compared with those who did not require replacement. Twenty-three
patients received replacement for hypofibrinogenemia (,1.5 g/L); 9 of them developed
marked hypofibrinogenemia (,1 g/L). Very low fibrinogen levels (,1 g/L) were documented
in patients before maximal CRS (n 5 1), during maximal CRS (n 5 7), and at CRS
improvement (n 5 1). Although hypofibrinogenemia was the most clinically significant
coagulopathy, some patients also developed prolonged prothrombin time and activated
partial thromboplastin time and increased international normalized ratio, further
increasing the risk of bleeding. Hypofibrinogenemia was effectively managed using
fibrinogen concentrate or cryoprecipitate replacement; severe (grade 4) bleeding events
were rare (n 5 2). CRS-associated coagulopathy with hypofibrinogenemia is manageable
according to empiric guidelines of fibrinogen replacement for CAR-T trials. Fibrinogen
concentrate should be used when cryoprecipitate is not reliably available. Monitoring
fibrinogen levels in patients with moderate or severe CRS is essential for avoiding
potentially fatal bleeding events. These trials were registered at www.clinicaltrials.gov as
#NCT02435849 and #NCT02228096.
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Introduction
Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell
(CAR-T) therapy that has been approved by the US Food and
Drug Administration, European Medicines Agency, Swissmedic, and
Japanese Pharmaceuticals and Medical Devices Agency. Tisagen-
lecleucel demonstrated high efficacy and a manageable safety
profile in a phase 2 multicenter global registration trial (ELIANA) and
a phase 2 multicenter trial in the United States (ENSIGN) in
pediatric and young adult patients with relapsed or refractory (r/r)
B-cell acute lymphoblastic leukemia (B-ALL).1-3 The most common
nonhematologic adverse event after tisagenlecleucel therapy is
cytokine release syndrome (CRS), a systemic inflammatory re-
sponse caused by the activation of immune cells and the release of
high levels of cytokines. As presented in the current report, any
grade CRS was observed in 79% of patients and grades 3 and 4
CRS in 42% in ELIANA and ENSIGN, respectively.
Coagulopathy with hypofibrinogenemia has been reported in
association with severe CRS in early reports of tisagenlecleucel
therapy in pediatric patients with r/r B-ALL.4,5 Severe hypofibrino-
genemia has also been reported in association with chemotherapy
and infection/sepsis and is used in the diagnostic criteria of
macrophage activation syndrome (MAS)/hemophagocytic lympho-
histiocytosis (HLH) (fibrinogen ,2.5 g/L and ,1.5 g/L, respec-
tively).6 In addition to secondary fibrinolysis through disseminated
intravascular coagulation (DIC), one hypothesis is that severely
reduced fibrinogen in MAS/HLH is caused by primary hyper-
fibrinogenolysis. For example, fibrinogen degradation may be linked
to plasminogen secretion by activated macrophages in response to
interleukin-1b and tumor necrosis factor production by activated
lymphocytes.7 MAS/HLH substantially overlaps CRS; they share
many clinical and laboratory features and pathophysiology, in-
cluding coagulopathy.8
CRS-associated coagulopathy, including DIC, prolonged prothrom-
bin time (PT)/activated partial thromboplastin time (aPTT), and
hypofibrinogenemia, is associated with moderate to severe CRS.9
Although PT and aPTT may be prolonged soon after the onset of
CRS, fibrinogen is an acute-phase reactant. Fibrinogen can be
elevated during the first few days of CRS and later decreased, often
to profoundly low levels, during maximal CRS and at the time of
CRS improvement. The risk of bleeding during this phase of
profound hypofibrinogenemia can be high, warranting close moni-
toring and replacement therapy.
In this report, we describe our global multicenter experience with
CRS-associated coagulopathy in 137 pediatric and young adult
patients with B-ALL treated with tisagenlecleucel in 2 trials. We also
present the clinical guidelines we developed for the management of
CRS-associated coagulopathy in the trials.
Materials and methods
Study design and patients
Details of the ELIANA and ENSIGN trials have been described
previously.2,3 Individual patient data from these 2 single-arm,
multicenter, phase 2 trials of tisagenlecleucel in pediatric and
young adult patients with r/r B-ALL were examined to further
characterize CRS-associated coagulopathy. Pooling of data was
possible because of the nearly identical study designs and
guidelines for grading and management of CRS. In brief, patients
enrolled in ELIANA and ENSIGN received lymphodepleting chemo-
therapy (fludarabine and cyclophosphamide) before a single
infusion of tisagenlecleucel. The patients were then monitored
for efficacy and safety outcomes.2 ELIANA enrolled and treated
patients at 25 global sites in 11 countries, and patients in
ENSIGN were treated at 13 sites in the United States. The study
protocols and all amendments were reviewed by the indepen-
dent ethics committee or institutional review board of each
center.
Cytokine release syndrome grading
CRS was graded according to the University of Pennsylvania
(Penn) grading scale, as previously described.10 Grade 1 was
considered a mild reaction treated with supportive care only. Grade
2 constituted a moderate reaction with some signs of organ
dysfunction related to CRS (grade 2 creatinine or grade 3 liver
function test results) and hospitalization for management of CRS-
related symptoms, including neutropenic fever and a need for IV
therapies (not including fluid resuscitation for hypotension) or
parenteral nutrition. Grade 3 was a more severe reaction requiring
hospitalization for the management of symptoms related to organ
dysfunction (grade 3 creatinine or grade 4 liver function test results)
related to CRS; hypotension treated with multiple IV fluid boluses or
low-dose vasopressors; coagulopathy requiring fresh frozen plasma
(FFP), cryoprecipitate, or fibrinogen concentrate; and hypoxemia
requiring supplemental oxygen via nasal cannula, high-flow oxygen,
bilevel positive airway pressure, or continuous positive airway
pressure. Grade 4 CRS involved life-threatening complications,
including hypotension requiring high-dose vasopressors or hypoxia
requiring mechanical ventilation.
CRS was managed according to a protocol-specific algorithm,
which is included in the Kymriah prescribing information.1 CRS was
considered to have resolved when patients were afebrile for
24 hours and vasopressors had been discontinued for 24 hours,
regardless of the resolution of other associated complications,
including coagulopathy.
Evaluation and management of coagulopathy after
tisagenlecleucel infusion
Coagulation panels, including PT or international normalized ratio
(INR), aPTT, and serum fibrinogen, were measured per protocol
in patient blood samples collected on the day of, but before,
tisagenlecleucel infusion, and on days 7, 14, and 28 after
tisagenlecleucel infusion. D-dimer levels were not consistently
measured by investigators; thus, data are not available. In patients
who developed CRS, coagulation panels were measured more
frequently during the clinical course, upon development of CRS,
and after resolution of CRS (per protocol, on days 2, 4, 7, 11, 14,
17, 21, and 28 after tisagenlecleucel infusion). Close monitoring
for additional levels of fibrinogen, PT or INR, and aPTT was
recommended in patients with severe CRS (grade 3 and 4),
patients receiving FFP and/or fibrinogen replacement, and/or
patients experiencing bleeding, as deemed clinically appropriate
by the physician. Frequent fibrinogen level monitoring was
recommended at least once per day in patients who had
hypofibrinogenemia or were receiving fibrinogen replacement for
severe bleeding and within 30 minutes of the initial fibrinogen
replacement infusion. Management of coagulopathy and replacement
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therapy with cryoprecipitate, fibrinogen concentrate, and/or FFP
was based on the investigator’s clinical judgment. Guidelines for
the management of hypofibrinogenemia were subsequently added
to the trial protocols.2 The use of fibrinogen concentrate vs
cryoprecipitate was based on local availability and the physician’s
judgment.
Statistical analysis
Individual patient data from the ELIANA and ENSIGN trials were
pooled in this analysis by using SAS software, version 9.4 (SAS
Institute). Characterization of CRS-associated coagulopathy includes
summary statistics. Nominal P-values were calculated by using
the x2 test without adjustment for multiplicity and should be
interpreted with caution. The analyses included in this manu-
script are exploratory in nature.
Results
Baseline demographics and disease characteristics
In total, 137 pediatric and young adult patients with B-ALL were
treated with tisagenlecleucel. Baseline demographics and disease
characteristics were examined in patients who developed different
grades of CRS and in patients who did not develop CRS. Age at
diagnosis, number of previous lines of therapy, and number of prior
allogeneic stem cell transplantations were generally balanced
among patients with (regardless of severity) and without CRS
(Table 1).
However, in the group of patients who developed severe CRS
(grades 3 and 4; 57 patients), a higher percentage of patients (46 of
57; 80.7%) had high blast counts ($50% blasts in bone marrow) at
enrollment, compared with patients experiencing no or low-grade
CRS (grades 0-2, 80 patients; 48 [60%] with $50% blasts).
Despite this association, blast measurement at enrollment may not
have been an accurate indicator of blast count at infusion, which
was not measured.
CRS and fibrinogen levels
Among patients who experienced CRS, the lowest mean and
median fibrinogen levels were observed in those with grade 4 CRS
(Table 2). Nine patients (8 with grade 4 CRS, 1 with grade 3)
reported severe hypofibrinogenemia (,1 g/L) during CRS. In
Table 1. Baseline demographics and disease burden by maximum CRS grade
No CRS (n 5 29)
Maximum CRS grade
Grade 1/2 (n 5 51) Grade 3 (n 5 27) Grade 4 (n 5 30) Grade 3/4 (n 5 57)
Age at initial diagnosis, y
Median (min-max) 7 (0-17) 6 (1-19) 8 (0-17) 9 (1-21) 8 (0-21)
Number of previous lines of therapy
Median (min-max) 3 (1-8) 3 (1-9) 4 (2-7) 3 (1-6) 3 (1-7)
Number of prior allogeneic stem cell transplantations, n (%)
0 11 (38) 24 (47) 11 (41) 17 (57) 28 (49)
1 15 (52) 26 (51) 13 (48) 12 (40) 25 (44)
2 3 (10) 1 (2) 3 (11) 1 (3) 4 (7)
Karnofsky/Lansky performance status
Median (min-max) 90 (50-100) 90 (50-100) 90 (70-100) 90 (50-100) 90 (50-100)
Leukemic blasts in bone marrow by flow cytometry, %
n 27 48 25 28 53
Median (min-max) 50 (0-97) 40 (0-96) 56 (1-99) 64 (2-97) 60 (1-99)
Bone marrow tumor burden at enrollment, n (%)*
,50% 10 (34.5) 22 (43.1) 6 (22.2) 5 (16.7) 11 (19.3)
$50% 19 (65.5) 29 (56.9) 21 (77.8) 25 (83.3) 46 (80.7)
CNS status, n (%)†
CNS-1 22 (75.9) 44 (86.3) 26 (96.3) 26 (86.7) 52 (91.2)
CNS-2 6 (20.7) 7 (13.7) 1 (3.7) 3 (10.0) 4 (7.0)
CNS-3 1 (3.4) 0 0 0 0
Unknown 0 0 0 1 (3.3) 1 (1.8)
Extramedullary disease, n (%)‡
Yes 6 (20.7) 7 (13.7) 1 (3.7) 2 (6.7) 3 (5.3)
No 23 (79.3) 44 (86.3) 26 (96.3) 28 (93.3) 54 (94.7)
CNS, central nervous system; CSF, cerebrospinal fluid; MRD, minimal residual disease.
*Includes MRD determined by flow cytometry and morphologic blast counts in bone marrow. If there are both MRD and morphologic results, the maximum is shown.
†The classification of CNS status includes the following: CNS-1, no lymphoblasts in the CSF regardless of WBC count; CNS-2, WBC ,5 cells/mL in the CSF, with the presence of
lymphoblasts; CNS-3, WBC of $5 cells/mL, with the presence of lymphoblasts.
‡Excludes CNS disease.
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1 patient with grade 4 CRS, fibrinogen levels were below the level
of detection (,0.4 g/L). Fibrinogen levels ,1 g/dL were not
reported in any patient with grade 1 or 2 CRS. Thus, patients with
grade 4 CRS developed severe hypofibrinogenemia more fre-
quently than patients with lower grades (nominal P , .001).
We also evaluated coagulation parameters and platelet and white
blood cell (WBC) counts within 48 hours of the lowest fibrinogen
level by CRS grade. Within this time frame, patients with grades 3
and 4 CRS had lower platelet and WBC counts and prolonged
aPTT and PT, compared with patients with grades 1 and 2 CRS
(Table 3).
Treatment and timing of
CRS-associated coagulopathy
Among patients with grades 3 and 4 CRS, baseline demographics
and disease characteristics were generally similar for those who
received fibrinogen concentrate or cryoprecipitate or did not
receive replacement therapy (supplemental Table 1). Replacement
therapy was given more frequently to patients ,10 years of age
(n 5 10; 43.5%) and all 5 Asian patients received replacement
therapy. Supplemental Table 2 presents baseline demographics
and disease characteristics for patients enrolled in the ELIANA and
ENSIGN trials. Use of fibrinogen concentrate or cryoprecipitate to
manage hypofibrinogenemia was only seen among the group of
patients with grades 3 and 4 CRS (Table 4). Four of 27 (14.8%)
patients with grade 3 CRS and 19 of 30 (63.3%) patients with
grade 4 CRS were treated with fibrinogen replacement therapy. No
patients had hypofibrinogenemia as the sole criterion for grades 3
and 4 CRS. From a regional perspective, cryoprecipitate was most
commonly used in the United States and was available at 18 sites in
the United States, Australia, Canada, and Germany. In contrast,
fibrinogen concentrate was the preferred option at the remaining 7
sites in Austria, Belgium, France, Italy, Japan, Norway, and Spain.
Overall, fibrinogen concentrate was used for replacement therapy in
fewer patients than cryoprecipitate (cryoprecipitate in 17 of 23
[73.9%] patients and fibrinogen concentrate in 6 of 23 patients
[26.1%]). FFP was used early during CRS coagulopathy at the
investigator’s discretion but was not recommended for management
of hypofibrinogenemia because of concerns of volume overload.
For patients with grades 3 and 4 CRS, the median time to onset
was 6 days (range, 2-33). The median duration of a grade 3 or 4
CRS episode was 10 days (range, 4-36). The median onset of
severe hypofibrinogenemia (,1 g/L) and peak ferritin was 8 days
(range, 4-13) and 9 days (range, 4-34), respectively. Fibrinogen
concentrate or cryoprecipitate was administered during the same
time frame at a median of 9 days, as well (range, 5-14; Table 5). Very
low fibrinogen levels (,1 g/L) were documented in patients before
maximal CRS (n 5 1), during maximal CRS (n 5 7), and at CRS
improvement (n 5 1).
Figure 1A-C shows the time course of fibrinogen, ferritin, PT, aPTT,
and CRS and the corresponding management in 3 representative
Table 2. Lowest fibrinogen level by CRS grade
Grade 1-2 (n 5 51) Grade 3 (n 5 27) Grade 4 (n 5 30) Patients with CRS (n 5 108) No CRS (n 5 29)
Lowest fibrinogen, g/L
Patients, n 44 26 30 100 29
Mean (SD) 3.7 (1.2) 3.2 (1.6) 1.8 (1.2) 3.0 (1.6) 2.7 (0.8)
Median 3.5 3.1 1.3 3.1 2.7
Min-max 1.4-6.3 0.9-6.8 0.4-5.5 0.4-6.8 0.8-3.8
Lowest fibrinogen category, n (%), g/L
,1 0 1 (3.7) 8 (26.7) 9 (8.3) 2 (6.9)
$1 to ,1.5 1 (2.0) 4 (14.8) 8 (26.7) 13 (12.0) 0
$1.5 43 (84.3) 21 (77.8) 14 (46.7) 78 (72.2) 27 (93.1)
Median reference range for fibrinogen across 2 age groups (6-10 y and 11-17 y) and 2 reagents 5 2.48-2.78 g/L.17 For patients with CRS, nadir fibrinogen is measured during CRS; for
patients without CRS, nadir fibrinogen is measured within 1 mo postinfusion.
SD, standard deviation.
Table 3. Maximum abnormalities of coagulation parameters and
platelets within 48 hours of lowest fibrinogen level by CRS grade
Patients, n Mean (SD) Median Min-max
Grade 1-2 CRS
Platelet, 3109/L 44 83.2 (69.4) 67.5 5.0-276.0
WBC, 3109/L 44 1.2 (1.2) 0.7 0-4.2
aPTT, s 42 37.3 (12.8) 34.3 25.0-100.4
PT, s 32 14.1 (1.7) 14.1 10.1-20.0
INR 27 1.1 (0.2) 1.1 0.9-1.7
Grade 3 CRS
Platelet, 3109/L 24 34.9 (29.5) 25.5 9.0-146.0
WBC, 3109/L 22 0.6 (0.8) 0.2 0-2.7
aPTT, s 23 42.4 (9.9) 40.8 27.1-66.4
PT, s 17 14.8 (3.5) 14.3 10.8-26.5
INR 16 1.3 (0.4) 1.2 1.0-2.5
Grade 4 CRS
Platelet, 3109/L 30 36.5 (26.5) 27.5 5.0-114.0
WBC, 3109/L 30 0.5 (1.1) 0.2 0-4.7
aPTT, s 26 63.0 (36.6) 49.4 31.3-200.0
PT, s 13 19.2 (9.3) 18.5 10.8-47.1
INR 19 1.6 (0.5) 1.5 1.0-3.0
Median reference ranges across 2 age groups (6-10 y and 11-17 y) and 2 reagents:
aPTT 5 31.0-32.8 s; PT 5 11.7-11.8 s; INR 5 1.04.17
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patients who needed treatment of CRS-associated coagulopathy
with fibrinogen concentrate or cryoprecipitate. Among all 3 represen-
tative patients, there was hyperferritinemia, prolonged PT and
aPTT, and hypofibrinogenemia during grades 3 and 4 CRS.
Bleeding events and CRS
At the beginning of the trial, the use of fibrinogen replacement was
based on the investigator’s judgement. Once the importance of
CRS-associated coagulopathy became apparent, specific guid-
ance for fibrinogen monitoring and replacement was developed.
Overall, of the 57 patients with grade 3 and 4 CRS, 23 received
fibrinogen replacement and 34 did not. Thirteen of the 23 patients
(57%) who received fibrinogen replacement at any time experi-
enced bleeding events within 8 weeks after infusion (highest grade
1 [n 5 1], grade 2 [n 5 6], grade 3 [n 5 4], and grade 4 [n 5 2]).
Among the 34 patients with grade 3 and 4 CRS who did not receive
fibrinogen replacement, 13 (38%) experienced bleeding events
(highest grade 1 [n 5 6], grade 2 [n 5 3], and grade 3 [n 5 4];
Table 6). Of note, median fibrinogen level was 1.15 g/L (range,
0.40-3.71) in patients with fibrinogen replacement compared with
3.12 g/L (range, 0.83-6.75) in patients without fibrinogen re-
placement. The lowest fibrinogen level by bleeding grade is shown
in Table 7. Six patients (2 each with grade 2, grade 3, and grade 4
bleeding) had severe hypofibrinogenemia (,1 g/L) during bleeding.
Five patients with severe hypofibrinogenemia (,1 g/L) experienced
no bleeding (Table 7).
Grade $3 bleeding was reported in 10 of the 57 patients
experiencing grade 3 and 4 CRS (17.5%; Table 6; supplemental
Table 3). Among those patients, 2 had severe hypofibrinogenemia
(,1 g/L), 1 of whom died of a fatal cerebral hemorrhage (grade 4
bleeding event) on day 14 after tisagenlecleucel infusion. When
coagulopathy with hypofibrinogenemia was detected 8 days after
infusion, the patient who died had resolving CRS, abdominal
compartment syndrome, and renal failure. The fibrinogen level
was 0.6 g/L, PT was 13.7 seconds, aPTT was 35.0 seconds, and
platelets were 76 3 109/L. The patient’s other medical conditions
included Down syndrome. The patient received 6 consecutive daily
doses of cryoprecipitate. On day 14 after infusion, the patient’s
aPTT had normalized, but fibrinogen remained low at 0.83 g/L.
Computed tomography of the head revealed acute parenchymal
hemorrhage, and the patient died of the bleeding event. The
hemorrhage was attributed to tisagenlecleucel and/or lymphode-
pleting chemotherapy. In addition, the patient’s leukemia, prior
chemotherapy, thrombocytopenia, coagulopathy, abdominal com-
partment syndrome, continuous venovenous hemodiafiltration (CVVH),
and hypertension were considered to be possible contributory
factors.
There was only 1 other patient with grade 4 bleeding (epistaxis,
hematuria, and hemoptysis, all grade 4). Fibrinogen replacement
was initiated based on clinical judgement (active bleeding);
fibrinogen levels were not reported.
Discussion
Consistent with the experience from an earlier single-center
study,11 CRS-associated coagulopathy with hypofibrinogenemia
was observed in pediatric and young adult patients with B-ALL who
were treated with tisagenlecleucel in the multicenter ELIANA and
ENSIGN trials. Coagulopathy with hypofibrinogenemia was more
frequent in patients who experienced severe CRS.5,9 Very low
fibrinogen levels (,1 g/L) were documented in patients before
maximal CRS (n 5 1), during maximal CRS (n 5 7), and at CRS
improvement (n 5 1). The need for frequent monitoring of serum
fibrinogen levels, even after the resolution of acute CRS symptoms,
was emphasized in the ELIANA and ENSIGN treatment protocols,
as fibrinogen levels may initially be elevated as an acute-phase
reactant during the acute CRS phase and then later decreased to
profoundly low levels, with increased risk of life-threatening
bleeding. Because the timing of severe hypofibrinogenemia can lag
behind the onset of severe CRS, close monitoring of fibrinogen
levels in patients with grade 3 or 4 CRS should be continued.
Because production of cryoprecipitate has been phased out
throughout much of the European Union12 and is not widely
available in Japan, fibrinogen concentrate (eg, RiaSTAP, Fibryga)
has become the preferred treatment of CRS-associated hypofi-
brinogenemia. Guidelines for the use of fibrinogen concentrate in
the treatment of CRS-associated hypofibrinogenemia were de-
veloped during the ELIANA and ENSIGN trials and have been
adapted based on clinical experience as guidelines for the
management of CRS-associated coagulopathy with hypofibrinoge-
nemia (Figure 2A).13,14 Among patients who experience grade 3 or
4 CRS, according to the Penn grading scale, fibrinogen levels
should be monitored frequently (at least once per day), and
replacement with fibrinogen concentrate should be instituted for
fibrinogen levels,1.5 g/L. Early on, adequate fibrinogen correction
Table 4. Fibrinogen concentrate or cryoprecipitate administration by CRS grade
Fibrinogen concentrate or cryoprecipitate administration Grade 1-2 (n 5 51) Grade 3 (n 5 27) Grade 4 (n 5 30) All patients (N 5 108)
Patients, n (%) 0 4 (14.8) 19 (63.3) 23 (21.3)
Fibrinogen concentrate, n (%) 0 1 (3.7) 5 (16.7) 6 (5.6)
Cryoprecipitate, n (%) 0 3 (11.1) 14 (46.7) 17 (15.7)
Table 5. Timing of onset, peak ferritin, and fibrinogen concentrate or
cryoprecipitate administration in patients with grade 3 or 4 CRS
Timing of onset, d
Patients, n Median Min-max
Onset of CRS episode 57 2 1-22
Onset of grade 3 or 4 CRS 57 6 2-33
Duration of CRS episode 57 10 4-36
Onset of fibrinogen ,1 g/L 9 8 4-13




Median duration and range for patients with maximum grade 3 or 4 CRS.
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should be assessed bymeasuring fibrinogen levels 30 to 60minutes
after the initial replacement infusion. If significant bleeding is
observed in CRS grades 3 and 4, hypofibrinogenemia should be
strongly suspected, even in the absence of known fibrinogen levels,
and replacement should be initiated. The initial dose of fibrinogen
concentrate is determined by the severity of the bleeding event and
the initial fibrinogen concentration. For minor bleeding events,
30 mg/kg can be safely administered, whereas 60 mg/kg is
recommended for major bleeding events (Figure 2A). Subsequent
doses can be calculated based on serum fibrinogen levels. Serum
fibrinogen should be closely monitored, especially in the context of
concurrent bleeding tendency or active bleeding, low platelets,
or anticoagulation, and replacement therapy should be adminis-
tered as needed to maintain fibrinogen levels of$1.5 g/L until CRS
is grade ,3. Late-onset hypofibrinogenemia may occur after grade
3 or 4 CRS; therefore, daily serum fibrinogen monitoring should be
considered until fibrinogen levels are maintained above the target
(without replacement) for at least 3 days.
In regions where cryoprecipitate is readily available or preferable,
institutional and administration guidelines should be followed. Each
unit of cryoprecipitate contains at least 150 mg of fibrinogen per
unit. Two units of cryoprecipitate per 10 kg of body weight generally
increases fibrinogen concentration by 1 g/L, except in cases of DIC
or continued bleeding with massive transfusion.14 Therefore, the
number of required cryoprecipitate units can be calculated as
follows: 0.2 3 weight (in kilograms) to provide ;1 g/L fibrinogen
(Figure 2B). Replacement therapy should be administered as
needed to achieve and maintain fibrinogen levels of $1.5 g/L, as
detailed for fibrinogen concentrate.
CRS-associated coagulopathy and hypofibrinogenemia were man-
aged with fibrinogen concentrate or cryoprecipitate replacement
during the ELIANA and ENSIGN trials. As a result, we developed
clinical guidelines for the ELIANA and ENSIGN trials for the
monitoring and management of CRS-associated hypofibrinogene-
mia and the use of fibrinogen concentrate. In patients who
developed grade 3 or 4 CRS, frequent monitoring of fibrinogen,
PT, aPTT, platelet levels, and signs of clinical bleeding was
recommended. Among the patients with grade 3 or 4 CRS who
did or did not receive fibrinogen replacement therapy, approximately
half in each group experienced bleeding events. However, patients
who received fibrinogen replacement seemed to have lower median
fibrinogen levels and were likely more prone to bleeding than those
who did not receive fibrinogen replacement. It is important to note
that at the beginning of the trial, there was no guidance provided for
managing hypofibrinogenemia, and the use of fibrinogen replace-
ment was based on investigator judgement. In some cases,
fibrinogen replacement was not initiated before the patients had
a clinically significant bleeding event.
CRS-associated hypofibrinogenemia increases the risk of bleed-
ing, and these patients should be appropriately monitored and
managed. Fortunately, severe bleeding events (grade 4) in the
context of low fibrinogen were uncommon and were reported in only
2 patients, 1 of whom had a fatal cerebral hemorrhage. It is likely
that other factors including, but not limited to, procoagulant and
anticoagulant factor abnormalities and thrombocytopenia contribute
to the incidence and severity of the bleeding. It is also possible that
the patients at the highest risk of bleeding received replacement,
which decreased their risk of bleeding to a level similar to that of the
patients who did not require replacement. In addition, some patients
received fibrinogen replacement when the bleeding was already
present, not before. As such, replacement cannot prevent a bleeding
event that has already occurred. Last, the guidelines for replacement
evolved over time, based on clinical experience, and replacement at
the beginning of the trial was based on investigator judgment and
clinical signs of bleeding rather than strict fibrinogen monitoring.
Patients with CRS-associated coagulopathy, as well as MAS/HLH
that occurs in the setting of CRS, should be monitored and
managed according to the proposed management guidelines for
hypofibrinogenemia. Coagulopathy with hypofibrinogenemia is also
a prominent feature and one of the diagnostic criteria of MAS/HLH,
a syndrome that substantially overlaps CRS. MAS/HLH encom-
passes a wide array of related life-threatening conditions, whereby
ineffective immune responses are characterized by an uncontrolled
hyperinflammatory response.15 The clinical presentation of MAS/
HLH includes fever, hepatosplenomegaly, cytopenias, hypertrigly-
ceridemia, liver dysfunction, elevated serum ferritin and trans-
aminases, coagulopathy with hypofibrinogenemia, and neurological
abnormalities. Laboratory parameters include highly elevated ferritin
(16 000-500 000 mg/dL) and decreased fibrinogen (,1.5 g/L).16
In patients with CRS-associated coagulopathy, we found low
fibrinogen levels that was out of proportion with other coagulation
parameters, such as PT and aPTT. This finding is consistent with
those in other reports of HLH in which low fibrinogen was reported
in most patients, some of whom still had normal levels of other
coagulation factors.15 The latest onset of hypofibrinogenemia
observed in the clinical trial was at day 13. Hypofibrinogenemia
Table 7. Lowest fibrinogen level by bleeding event grade
Lowest fibrinogen category, g/L, n (%)
Bleeding event, grade <1 ‡1 to <1.5 ‡1.5
No bleeding 5 (16.7) 9 (30) 16 (53.3)
1 0 1 (14.3) 6 (85.7)
2 2 (22.2) 2 (22.2) 5 (55.6)
3 2 (25) 0 6 (75)
4 0 0 2 (100)
Table 6. Bleeding events in patients with grade 3 or 4 CRS, with and
without fibrinogen replacement therapy
Fibrinogen replacement therapy
Yes, n 5 23 No, n 5 34
Lowest fibrinogen, n 23 33*
Lowest fibrinogen, median (range), g/L 1.15 (0.40-3.71) 3.12 (0.83-6.75)
Bleeding event, n (%)† n 5 23 n 5 34
No bleeding 10 (43) 21 (62)
Any grade 13 (57) 13 (38)
Grade 1 1 (4) 6 (18)
Grade 2 6 (26) 3 (9)
Grade 3 4 (17) 4 (18)
Grade 4 2 (9) 0
Bleeding event grade corresponds to maximum grade.
*One patient did not have a documented fibrinogen level.
†Number of patients with an event.
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often occurs as the patient begins to improve systemically;
as a result, hypofibrinogenemia may be overlooked in these
patients. Thus, low fibrinogen is a particularly sensitive indicator
of CRS-associated coagulopathy and should be frequently
monitored during and after grade 3 or 4 CRS. In patients who
experience grade 3 or 4 CRS in the absence of bleeding,
fibrinogen levels should be monitored daily until the resolution
of CRS and until fibrinogen levels are $1.5 g/L without replacement
for 3 days.
The current management guidelines were developed based on
CRS grading from the Penn grading scale. The most recent
American Society for Transplantation and Cellular Therapy (ASTCT)
consensus scale grades CRS severity mainly by hypotension and
hypoxia. Significant organ toxicities and coagulopathy are not part of
the grading system.8 Differences between the Penn and ASTCT
grading scales include the use of intervention for hypoxia as a grade 3
event (Penn) vs a grade 2 event (ASTCT). In addition, hypoxia
requiring positive pressure is considered a grade 3 event (Penn) vs
a grade 4 event (ASTCT). Centers using the ASTCT grading scale
should consider implementing the guidelines for management of
potential CRS-associated coagulopathy in cases wherein mild
intervention is used for treatment of hypoxia (grade 2). However,
the management guidelines presented in this report are applicable to
all patients with severe CRS (grades 3 and 4), regardless of the
applied grading scale.
As part of the clinical guidelines for managing CRS-associated
coagulopathy and hypofibrinogenemia, replacement of fibrinogen
with cryoprecipitate or fibrinogen concentrate, rather than FFP, is
preferred to avoid fluid overload in these patients. In addition,
severe CRS is commonly associated with capillary leak syndrome,
in which hyperpermeability of capillaries allows fluid to leak into
the lungs and interstitial tissues, which can be worsened by fluid
overload,16 another reason that fibrinogen supplementation should
be provided through cryoprecipitate or fibrinogen concentrates.
For fibrinogen replacement with fibrinogen concentrate, weight-
adjusted dosing is recommended for maintenance of adequate
fibrinogen levels.
In addition to monitoring fibrinogen levels and PT/aPTT, platelet
counts should also be monitored closely. Platelet transfusion should
be administered as appropriate to prevent added risk of bleeding in
the context of severe thrombocytopenia and coagulopathy.
Concurrent clinical events and laboratory abnormalities can further
complicate the course of treatment, increase the risk of bleeding,
and present challenges for the management of coagulopathy in the
context of CRS. Ongoing thrombocytopenia, uncontrolled hyper-
tension after withdrawal of vasopressors, and the use of CVVH with
anticoagulation for renal replacement therapy often contribute to
observed bleeding. For example, the patient who experienced
a fatal cerebral hemorrhage had undergone CVVH with continued
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High fevers (day 2-9)
Vasopressor (day 6-10)
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Cryoprecipitate (106 and 92 mL)
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PT (s)
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CRS Gr 3 (day 7-30) CRS Resolved (day 30)
High fevers (day 2-29)
Vasopressors (Norepinephrine day 2; Epinephrine day 7)
CVVH (day 7-17)





Figure 1. Time course of treatment of CRS-associated coagulopathy on
patients treated with tisagenlecleucel. Patient 1 (A), patient 2 (B), patient 3
(C). Days after tisagenlecleucel infusion; day 1, infusion day. Arrows, the day of
blood product replacement with fibrinogen concentrate; orange triangles, CRS onset
by grade; blue triangles, CRS resolution. ALL, acute lymphoblastic leukemia; Gr,
grade; ICU, intensive care unit; s/p, status post; SCT, stem cell transplantation.
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treatment with furosemide. It is important to note that the risk of
bleeding may outweigh the risk of thrombosis in this setting, and
caution should be exercised when considering anticoagulants such
as low-dose heparin.
In summary, monitoring of patients with CRS-associated coagul-
opathy and hypofibrinogenemia is imperative to avoid the potential
for bleeding events and even life-threatening hemorrhage. Fibrino-
gen monitoring and replacement with fibrinogen concentrate or
cryoprecipitate according to the guidelines developed for the
ELIANA and ENSIGN trials is an effective strategy and the
recommended treatment option in these patients.
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